Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
TRIB's Cash to Debt is ranked higher than
95% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. TRIB: No Debt )
Ranked among companies with meaningful Cash to Debt only.
TRIB' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: No Debt

Equity to Asset 0.82
TRIB's Equity to Asset is ranked higher than
80% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. TRIB: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
TRIB' s 10-Year Equity to Asset Range
Min: 0.29   Max: 0.88
Current: 0.82

0.29
0.88
Interest Coverage 261.43
TRIB's Interest Coverage is ranked lower than
52% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 801.71 vs. TRIB: 261.43 )
Ranked among companies with meaningful Interest Coverage only.
TRIB' s 10-Year Interest Coverage Range
Min: 0.73   Max: 9999.99
Current: 261.43

0.73
9999.99
F-Score: 6
Z-Score: 7.27
M-Score: -2.36
WACC vs ROIC
5.74%
9.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 17.00
TRIB's Operating margin (%) is ranked higher than
89% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. TRIB: 17.00 )
Ranked among companies with meaningful Operating margin (%) only.
TRIB' s 10-Year Operating margin (%) Range
Min: -56.78   Max: 67.5
Current: 17

-56.78
67.5
Net-margin (%) 16.00
TRIB's Net-margin (%) is ranked higher than
93% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. TRIB: 16.00 )
Ranked among companies with meaningful Net-margin (%) only.
TRIB' s 10-Year Net-margin (%) Range
Min: -55.5   Max: 67.4
Current: 16

-55.5
67.4
ROE (%) 8.59
TRIB's ROE (%) is ranked higher than
70% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. TRIB: 8.59 )
Ranked among companies with meaningful ROE (%) only.
TRIB' s 10-Year ROE (%) Range
Min: -76.72   Max: 54.77
Current: 8.59

-76.72
54.77
ROA (%) 7.04
TRIB's ROA (%) is ranked higher than
80% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.19 vs. TRIB: 7.04 )
Ranked among companies with meaningful ROA (%) only.
TRIB' s 10-Year ROA (%) Range
Min: -45.03   Max: 41.2
Current: 7.04

-45.03
41.2
ROC (Joel Greenblatt) (%) 31.10
TRIB's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.66 vs. TRIB: 31.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TRIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -123.71   Max: 122.5
Current: 31.1

-123.71
122.5
Revenue Growth (3Y)(%) 8.00
TRIB's Revenue Growth (3Y)(%) is ranked higher than
61% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. TRIB: 8.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TRIB' s 10-Year Revenue Growth (3Y)(%) Range
Min: -30.9   Max: 108.2
Current: 8

-30.9
108.2
EBITDA Growth (3Y)(%) 0.30
TRIB's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. TRIB: 0.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TRIB' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -45.8   Max: 125.1
Current: 0.3

-45.8
125.1
EPS Growth (3Y)(%) 1.40
TRIB's EPS Growth (3Y)(%) is ranked higher than
51% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. TRIB: 1.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TRIB' s 10-Year EPS Growth (3Y)(%) Range
Min: -52.9   Max: 75.6
Current: 1.4

-52.9
75.6
» TRIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

TRIB Guru Trades in Q2 2014

Jim Simons 451,050 sh (+0.17%)
Chuck Royce 265,000 sh (-4.99%)
» More
Q3 2014

TRIB Guru Trades in Q3 2014

Chuck Royce 265,000 sh (unchged)
Jim Simons 430,150 sh (-4.63%)
» More
Q4 2014

TRIB Guru Trades in Q4 2014

Zeke Ashton 135,000 sh (New)
Chuck Royce 365,792 sh (+38.03%)
Jim Simons 324,929 sh (-24.46%)
» More
Q1 2015

TRIB Guru Trades in Q1 2015

Chuck Royce 371,000 sh (+1.42%)
Zeke Ashton 135,000 sh (unchged)
Jim Simons 246,954 sh (-24.00%)
» More
» Details

Insider Trades

Latest Guru Trades with TRIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.00
TRIB's P/E(ttm) is ranked higher than
93% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.40 vs. TRIB: 14.00 )
Ranked among companies with meaningful P/E(ttm) only.
TRIB' s 10-Year P/E(ttm) Range
Min: 2.08   Max: 69.1
Current: 14

2.08
69.1
Forward P/E 25.06
TRIB's Forward P/E is ranked lower than
69% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.34 vs. TRIB: 25.06 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 14.00
TRIB's PE(NRI) is ranked higher than
92% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.80 vs. TRIB: 14.00 )
Ranked among companies with meaningful PE(NRI) only.
TRIB' s 10-Year PE(NRI) Range
Min: 2.08   Max: 48.33
Current: 14

2.08
48.33
P/B 0.50
TRIB's P/B is ranked higher than
98% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. TRIB: 0.50 )
Ranked among companies with meaningful P/B only.
TRIB' s 10-Year P/B Range
Min: 0.18   Max: 3.49
Current: 0.5

0.18
3.49
P/S 3.70
TRIB's P/S is ranked lower than
59% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. TRIB: 3.70 )
Ranked among companies with meaningful P/S only.
TRIB' s 10-Year P/S Range
Min: 0.16   Max: 6.93
Current: 3.7

0.16
6.93
POCF 16.70
TRIB's POCF is ranked higher than
64% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.74 vs. TRIB: 16.70 )
Ranked among companies with meaningful POCF only.
TRIB' s 10-Year POCF Range
Min: 1.91   Max: 592
Current: 16.7

1.91
592
EV-to-EBIT 22.15
TRIB's EV-to-EBIT is ranked higher than
56% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. TRIB: 22.15 )
Ranked among companies with meaningful EV-to-EBIT only.
TRIB' s 10-Year EV-to-EBIT Range
Min: -1.7   Max: 98.5
Current: 22.15

-1.7
98.5
Shiller P/E 13.80
TRIB's Shiller P/E is ranked higher than
96% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TRIB: 13.80 )
Ranked among companies with meaningful Shiller P/E only.
TRIB' s 10-Year Shiller P/E Range
Min: 2.02   Max: 1275
Current: 13.8

2.02
1275
Current Ratio 3.42
TRIB's Current Ratio is ranked higher than
60% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. TRIB: 3.42 )
Ranked among companies with meaningful Current Ratio only.
TRIB' s 10-Year Current Ratio Range
Min: 1   Max: 9.17
Current: 3.42

1
9.17
Quick Ratio 1.63
TRIB's Quick Ratio is ranked lower than
65% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. TRIB: 1.63 )
Ranked among companies with meaningful Quick Ratio only.
TRIB' s 10-Year Quick Ratio Range
Min: 0.44   Max: 7.6
Current: 1.63

0.44
7.6
Days Inventory 224.23
TRIB's Days Inventory is ranked lower than
94% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 72.34 vs. TRIB: 224.23 )
Ranked among companies with meaningful Days Inventory only.
TRIB' s 10-Year Days Inventory Range
Min: 70.32   Max: 324.82
Current: 224.23

70.32
324.82
Days Sales Outstanding 96.77
TRIB's Days Sales Outstanding is ranked lower than
77% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. TRIB: 96.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
TRIB' s 10-Year Days Sales Outstanding Range
Min: 47.9   Max: 177.43
Current: 96.77

47.9
177.43

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
TRIB's Dividend Yield is ranked higher than
90% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TRIB: 1.30 )
Ranked among companies with meaningful Dividend Yield only.
TRIB' s 10-Year Dividend Yield Range
Min: 0.72   Max: 1.36
Current: 1.3

0.72
1.36
Dividend Payout 0.30
TRIB's Dividend Payout is ranked lower than
54% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.27 vs. TRIB: 0.30 )
Ranked among companies with meaningful Dividend Payout only.
TRIB' s 10-Year Dividend Payout Range
Min: 0.63   Max: 1.21
Current: 0.3

0.63
1.21
Dividend growth (3y) 30.10
TRIB's Dividend growth (3y) is ranked higher than
90% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.70 vs. TRIB: 30.10 )
Ranked among companies with meaningful Dividend growth (3y) only.
TRIB' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 30.1
Current: 30.1

0
30.1
Yield on cost (5-Year) 1.30
TRIB's Yield on cost (5-Year) is ranked higher than
67% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.75 vs. TRIB: 1.30 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TRIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.72   Max: 1.36
Current: 1.3

0.72
1.36
Share Buyback Rate -2.20
TRIB's Share Buyback Rate is ranked higher than
55% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.50 vs. TRIB: -2.20 )
Ranked among companies with meaningful Share Buyback Rate only.
TRIB' s 10-Year Share Buyback Rate Range
Min: 26.2   Max: -79.2
Current: -2.2

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 4.00
TRIB's Price/Net Current Asset Value is ranked lower than
254% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. TRIB: 4.00 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TRIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 320
Current: 4

0.61
320
Price/Tangible Book 1.87
TRIB's Price/Tangible Book is ranked higher than
80% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. TRIB: 1.87 )
Ranked among companies with meaningful Price/Tangible Book only.
TRIB' s 10-Year Price/Tangible Book Range
Min: 0.45   Max: 225
Current: 1.87

0.45
225
Price/DCF (Projected) 0.65
TRIB's Price/DCF (Projected) is ranked higher than
97% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. TRIB: 0.65 )
Ranked among companies with meaningful Price/DCF (Projected) only.
TRIB' s 10-Year Price/DCF (Projected) Range
Min: 0.38   Max: 78.35
Current: 0.65

0.38
78.35
Price/Median PS Value 1.62
TRIB's Price/Median PS Value is ranked lower than
105% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. TRIB: 1.62 )
Ranked among companies with meaningful Price/Median PS Value only.
TRIB' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 5.51
Current: 1.62

0.17
5.51
Price/Graham Number 0.71
TRIB's Price/Graham Number is ranked higher than
97% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. TRIB: 0.71 )
Ranked among companies with meaningful Price/Graham Number only.
TRIB' s 10-Year Price/Graham Number Range
Min: 0.26   Max: 11.25
Current: 0.71

0.26
11.25
Earnings Yield (Greenblatt) 4.50
TRIB's Earnings Yield (Greenblatt) is ranked higher than
74% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. TRIB: 4.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
TRIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 56.6
Current: 4.5

1
56.6
Forward Rate of Return (Yacktman) -18.30
TRIB's Forward Rate of Return (Yacktman) is ranked lower than
96% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.51 vs. TRIB: -18.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
TRIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -32.7   Max: 10.1
Current: -18.3

-32.7
10.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TRBA.Germany,
Trinity Biotech PLC was incorporated as a public limited company, registered in Ireland in January 1992. The Company commenced operations in 1992 and, in October 1992, completed an initial public offering of its securities in the US. The Company develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. It is also a provider of raw materials to the life sciences industry. The Company markets its portfolio of almost 850 products to customers in approximately 100 countries around the world through its own sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's tests remains the USA. The Company develops, acquires, manufactures and markets clinical in-vitro diagnostic products. It supplies the clinical laboratory segment of the in-vitro diagnostic market. It also sells raw materials to the life sciences industry. Its Point-of-Care product is Unigold (tm), which tests for the presence of HIV antibodies. It sells its product through its own direct sales-force in four countries: the United States, Germany, France and the United Kingdom. Its competitors are Abbott Diagnostics, Alere Inc., Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens (from the combined acquisitions of Bayer, Dade-Behring and DPC), Thermo Fisher, Tosoh and Werfen. The preclinical and clinical testing, manufacture, labelling, distribution, and promotion of Trinity Biotech's products are subject to extensive and rigorous government regulation in the United States and in other countries in which its products are sought to be marketed.
» More Articles for TRIB

Headlines

Articles On GuruFocus.com

More From Other Websites
Trinity Biotech Announces Q1 2015 Financial Results Apr 30 2015
Trinity Biotech Announces Quarter 1 Results -- EPS 17.4 Cents Dividend of 22 Cents Apr 30 2015
Q1 2015 Trinity Biotech PLC Earnings Release - Time Not Supplied Apr 30 2015
Trinity Biotech to Announce Q1 2015 Financial Results Apr 23 2015
Trinity Biotech plc to Announce First Quarter Fiscal Year 2015 Financial Results Apr 23 2015
Trinity Biotech Closes Offering of $115m of 4% Exchangeable Senior Notes due 2045 Apr 09 2015
Trinity Biotech plc Closes Offering of $115 Million of 4.00% Exchangeable Senior Notes Due 2045,... Apr 09 2015
Trinity Biotech (TRIB) in Focus: Stock Tumbles 9.4% - Tale of the Tape Apr 06 2015
Trinity Biotech plc Prices Offering of $100 Million of 4.00% Exchangeable Senior Notes due 2045 Apr 02 2015
Trinity Biotech plc Announces Proposed Offering of $100 Million of Exchangeable Senior Notes due... Apr 01 2015
TRINITY BIOTECH PLC Financials Mar 28 2015
Trinity Biotech Announces Filing of 2014 Annual Report Mar 25 2015
Trinity Biotech Announces Q4 and FY 2014 Financial Results Mar 03 2015
Trinity Biotech Announces Results for Q4 and Fiscal Year 2014 Mar 03 2015
Q4 2014 Trinity Biotech PLC Earnings Release - Time Not Supplied Mar 03 2015
Trinity Biotech to Announce Q4 and FY 2014 Financial Results Feb 25 2015
Trinity Biotech Announces Recommencement of US Clinical Trials for Troponin I Product Feb 23 2015
Trinity Biotech Announces CLIA waiver of Rapid Syphilis Test Dec 16 2014
Weakness Seen in Trinity Biotech (TRIB): Stock Tumbles 7.8% Oct 24 2014
Trinity Biotech Announces Q3 2014 Financial Results Oct 23 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK